Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Research & Development (2017 - 2025)

Lexaria Bioscience's Research & Development history spans 9 years, with the latest figure at $671340.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 65.63% year-over-year to $671340.0; the TTM value through Nov 2025 reached $7.0 million, up 86.05%, while the annual FY2025 figure was $8.2 million, 249.02% up from the prior year.
  • Research & Development for Q4 2025 was $671340.0 at Lexaria Bioscience, down from $1.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.7 million in Q2 2025 and bottomed at $176398.0 in Q1 2021.
  • The 5-year median for Research & Development is $622915.5 (2023), against an average of $892534.6.
  • The largest annual shift saw Research & Development skyrocketed 1750.56% in 2021 before it crashed 65.63% in 2025.
  • A 5-year view of Research & Development shows it stood at $458709.0 in 2021, then skyrocketed by 80.83% to $829489.0 in 2022, then crashed by 30.74% to $574491.0 in 2023, then skyrocketed by 239.99% to $2.0 million in 2024, then plummeted by 65.63% to $671340.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Research & Development are $671340.0 (Q4 2025), $1.9 million (Q3 2025), and $2.7 million (Q2 2025).